Malnutrition
Drug research and approvals for malnutrition: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 216 studies of malnutrition are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 216
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Impact of Advanced Parkinson Therapies on Clinical Status: Deep Brain Stimulation and Foslevodopa/FoscarbidopaNCT07944859 · Not reported · Medical University of Warsaw · starts Mar 19, 2025
- Bone Deterioration After Kidney Transplantation Assessed by DXA and HR-pQCTNCT07935915 · Not reported · Medical University Innsbruck · starts Oct 21, 2026
- Role of Vitamin D Supplementation in Children With Irritable Bowel SyndromeNCT07914478 · Not applicable · Aziz Bhatti Shaheed Teaching Hospital · starts Sep 1, 2026
- The Effects of Increased Water Intake on Muscle Function, Physical Performance, and Endocrine Regulation in…NCT07892742 · Not applicable · Polytechnic University of Santarém · starts Jan 1, 2027
- Impact of Trout Fish, Cow Milk With Egg, Vitamin D Supplementation, and Dietary Education on Vitamin D Status,…NCT07864662 · Not applicable · Aga Khan University · starts Aug 10, 2026
- Development of a Digital Personalised Nutrition Tool for Adolescents Undergoing Cancer TreatmentNCT07865117 · Not applicable · KU Leuven · starts Sep 1, 2026
- SHIFT-TB: Nutrition Intervention and EvaluationNCT07836322 · Not applicable · National University of Singapore · starts Oct 28, 2026
- Hospital-Based Prospective Cohort of Malnutrition Under 6-Month Study (HOSPIC-6-Study)NCT07831343 · Not reported · Universitas Indonesia · starts Aug 28, 2026
- Relaxation Intervention to Improve Newborn Growth and Maternal Well-beingNCT07774793 · Not applicable · University of California, San Francisco · starts Aug 20, 2026
Phase 3 9
- AzithromycinBacterial 70S ribosome inhibitor
- AlbendazoleTubulin inhibitor
- AmoxicillinBacterial penicillin-binding protein inhibitor
- Glutamine
- Glycine
- Testosterone undecanoateAndrogen Receptor agonist
- Amylase (pancrelipase)Starch hydrolytic enzyme
- Retinol
- Starch
Phase 2 12 of 13
- MetronidazoleDNA inhibitor
- BudesonideGlucocorticoid receptor agonist
- CholecalciferolVitamin D receptor agonist
- ErgocalciferolVitamin D receptor agonist
- TeduglutideGlucagon-like peptide 2 receptor agonist
- Nandrolone decanoateAndrogen Receptor agonist
- CeftriaxoneBacterial penicillin-binding protein inhibitor
- NitazoxanidePyruvate:ferredoxin oxidoreductase inhibitor
- Bifidobacterium spp.Probiotic
- Dextrose
- Niacinamide
- Amino acids
Phase 1 or earlier 2
- OxandroloneAndrogen Receptor agonist
- MesalamineArachidonate 5-lipoxygenase inhibitor
How its trials ended
1,499 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 219 whose ending is known, 56% met their primary endpoint, 10% missed it and 34% stopped early.
- Completed, result not reported82655%
- Ongoing24116%
- Status unknown21314%
- Met its primary endpoint1228%
- Stopped: other or unclear503%
- Missed its primary endpoint221%
- Stopped: enrollment or feasibility141%
- Stopped: sponsor or business decision5<1%
- Stopped: lack of efficacy4<1%
- Stopped: funding2<1%
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Mar 18, 1994 | OxandroloneTreatment of moderate/severe acute alcoholic hepatitis in the presence of moderate protein calorie malnutrition. | Bio-Technology General Corp. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA